This news release discloses the company’s EBITDA for the three-month and 12-month periods ending Dec. 31, 2020 and 2019. The company believes that including the EBITDA results assists investors in assessing the company’s operational performance relative to its competitors. A reconciliation of EBITDA to GAAP net income is included with this news release.
Forward-Looking Statements
This release contains “forward-looking statements” including statements regarding as we expand our systems and software offerings, we may see larger differences between bookings and revenue on a quarterly basis; the areas where we have focused showed strength and momentum increased throughout the year; I believe we enter 2021 in a position of strength and poised to accelerate growth and deliver increased value to all our stakeholders; I believe our strong close to 2020 is proof in our ability to adapt quickly to the global pandemic; we remain committed to our 2023 financial model; in order to accelerate growth, we will continue to align investments to our higher growth opportunities within our four strategic pillars; I believe our strong balance sheet gives us the opportunity to capitalize on inorganic investments to meet our growth targets faster and deliver shareholder returns; expecting Q1 revenue to be in the range of $324 million to $354 million; expecting Q1 non-GAAP revenue to be in the range of $325 million to $355 million; expecting that GAAP diluted EPS will be in the range of $(0.05) to $0.09 for Q1, with non-GAAP diluted EPS expected to be in the range of $0.24 to $0.38; and estimating its non-GAAP effective tax rate to be approximately 17 percent to 18 percent for 2021. These statements are subject to a number of risks and uncertainties, including risks and uncertainties related to the COVID-19 virus and further economic and market disruptions resulting from COVID-19; further adverse changes or fluctuations in the global economy; further adverse fluctuations in our industry, foreign exchange fluctuations, changes in the current global trade regulatory environment; fluctuations in customer demands and markets; fluctuations in demand for our products including orders from our large customers; component shortages; delays in the release of new products; our ability to effectively manage our operating expenses; manufacturing inefficiencies and the level of capacity utilization; the impact of any recent or future acquisitions or divestitures by NI (including the ability to successfully operate or integrate the acquired company’s business into NI, the ability to retain and integrate the acquired company’s employees into NI, and the ability to realize the expected benefits of the acquisition); our ability to achieve the benefits of employee restructuring plans and possible changes in the size and timing of the related charges; cyber-attacks; expense overruns; and adverse effects of price changes or effective tax rates. Actual results may differ materially from the expected results. The company directs readers to its Form 10-K for the year ended Dec. 31, 2019, its Form 10-Q for the quarter ended Sept. 30, 2020 and the other documents it files with the SEC for other risks associated with the company’s future performance. These documents contain and identify important factors that could cause our actual results to differ materially from those contained in our forward-looking statements.
All information in this release is as of the date above. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.
About NI
At NI, we bring together the people, ideas and technology so forward thinkers and creative problem solvers can take on humanity’s biggest challenges. From data and automation to research and validation, we provide the tailored, software-connected systems engineers and enterprises need to Engineer Ambitiously™ every day. (NATI-F)
National Instruments, NI and ni.com are trademarks of National Instruments. Other product and company names listed are trademarks or trade names of their respective companies.
National Instruments |
|||||||
Condensed Consolidated Balance Sheets |
|||||||
(in thousands) |
|||||||
|
December 31, |
December 31, |
|||||
|
2020 |
2019 |
|||||
|
(unaudited) |
|
|||||
ASSETS |
|
|
|||||
Current assets: |
|
|
|||||
Cash and cash equivalents |
$ |
260,232 |
|
$ |
194,616 |
|
|
Short-term investments |
59,923 |
|
237,983 |
|
|||
Accounts receivable, net |
266,869 |
|
248,872 |
|
|||
Inventories, net |
194,012 |
|
200,410 |
|
|||
Prepaid expenses and other current assets |
68,470 |
|
65,477 |
|
|||
Total current assets |
849,506 |
|
947,358 |
|
|||
Property and equipment, net |
254,399 |
|
243,717 |
|
|||
Goodwill |
467,547 |
|
262,242 |
|
|||
Intangible assets, net |
172,719 |
|
84,083 |
|
|||
Operating lease right-of-use assets |
67,674 |
|
70,407 |
|
|||
Other long-term assets |
79,670 |
|
44,082 |
|
|||
Total assets |
1,891,515 |
|
1,651,889 |
|
|||
|
|
|
|||||
LIABILITIES AND EQUITY |
|
|
|||||
Current liabilities: |
|
|
|||||
Accounts payable and accrued liabilities |
51,124 |
|
52,192 |
|
|||
Accrued compensation |
87,068 |
|
47,732 |
|
|||
Deferred revenue - current |
132,151 |
|
131,445 |
|
|||
Other lease liabilities - current |
15,801 |
|
13,431 |
|
|||
Other taxes payable |
48,129 |
|
40,607 |
|
|||
Debt - current |
5,000 |
|
— |
|
|||
Other current liabilities |
42,578 |
|
20,716 |
|
|||
Total current liabilities |
381,851 |
|
306,123 |
|
|||
Deferred income taxes |
25,287 |
|
14,065 |
|
|||
Liability for uncertain tax positions |
10,868 |
|
6,652 |
|
|||
Income tax payable - non-current |
61,623 |
|
69,151 |
|
|||
Deferred revenue - long-term |
36,335 |
|
33,480 |
|
|||
Operating lease liabilities - non-current |
35,854 |
|
40,650 |
|
|||
Debt, non-current |
92,036 |
|
— |
|
|||
Other long-term liabilities |
22,789 |
|
5,418 |
|
|||
Total liabilities |
666,643 |
|
475,539 |
|
|||
|
|
|
|||||
Stockholders' equity: |
|
|
|||||
Preferred stock |
— |
|
— |
|
|||
Common stock |
1,312 |
|
1,305 |
|
|||
Additional paid-in capital |
1,033,285 |
|
953,578 |
|
|||
Retained earnings |
211,101 |
|
242,537 |
|
|||
Accumulated other comprehensive loss |
(20,826) |
|
(21,070) |
|
|||
Total stockholders' equity |
1,224,872 |
|
1,176,350 |
|
|||
Total liabilities and stockholders' equity |
$ |
1,891,515 |
|
$ |
1,651,889 |
|
National Instruments |
|||||||||||||||
Condensed Consolidated Statements of Income |
|||||||||||||||
(in thousands, except per share data, unaudited) |
|||||||||||||||
|
|
|
|
|
|||||||||||
|
Three Months Ended |
|
Years Ended |
||||||||||||
|
December 31, |
|
December 31, |
||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||
|
|
|
|
|
|
||||||||||
Net sales: |
|
|
|
|
|
||||||||||
Product |
$ |
327,714 |
|
$ |
332,267 |
|
|
$ |
1,137,603 |
|
$ |
1,215,014 |
|
||
Software maintenance |
40,124 |
|
35,201 |
|
|
149,068 |
|
138,201 |
|
||||||
Total net sales |
367,838 |
|
367,468 |
|
|
1,286,671 |
|
1,353,215 |
|
||||||
|
|
|
|
|
|
||||||||||
Cost of sales: |
|
|
|
|
|
||||||||||
Product |
105,625 |
|
89,308 |
|
|
359,861 |
|
329,364 |
|
||||||
Software maintenance |
3,571 |
|
1,827 |
|
|
11,260 |
|
7,527 |
|
||||||
Total cost of sales |
109,196 |
|
91,135 |
|
|
371,121 |
|
336,891 |
|
||||||
|
|
|
|
|
|
||||||||||
Gross profit |
258,642 |
|
276,333 |
|
|
915,550 |
|
1,016,324 |
|
||||||
|
70% |
75% |
|
71% |
75% |
||||||||||
Operating expenses: |
|
|
|
|
|
||||||||||
Sales and marketing |
134,570 |
|
121,052 |
|
|
465,509 |
|
473,392 |
|
||||||
Research and development |
73,733 |
|
71,471 |
|
|
280,381 |
|
272,452 |
|
||||||
General and administrative |
36,883 |
|
30,129 |
|
|
129,863 |
|
122,768 |
|
||||||
Total operating expenses |
245,186 |
|
222,652 |
|
|
875,753 |
|
868,612 |
|
||||||
Gain on sale of business/asset |
— |
|
— |
|
|
159,753 |
|
26,842 |
|
||||||
Operating income |
13,456 |
|
53,681 |
|
|
199,550 |
|
174,554 |
|
||||||
|
|
|
|
|
|
||||||||||
Other income (expense) |
1,797 |
|
611 |
|
|
(788) |
|
5,990 |
|
||||||
|
|
|
|
|
|
||||||||||
Income before income taxes |
15,253 |
|
54,292 |
|
|
198,762 |
|
180,544 |
|
||||||
|
|
|
|
|
|
||||||||||
Provision (Benefit) for income taxes |
10,515 |
|
(4,304) |
|
|
55,103 |
|
18,393 |
|
||||||
|
|
|
|
|
|
||||||||||
Net income |
$ |
4,738 |
|
$ |
58,596 |
|
|
$ |
143,659 |
|
$ |
162,151 |
|
||
|
|
|
|
|
|
||||||||||
Basic earnings per share |
$ |
0.04 |
|
$ |
0.45 |
|
|
$ |
1.10 |
|
$ |
1.23 |
|
||
Diluted earnings per share |
$ |
0.04 |
|
$ |
0.45 |
|
|
$ |
1.09 |
|
$ |
1.22 |
|
||
|
|
|
|
|
|
||||||||||
Weighted average shares outstanding - |
|
|
|
|
|
||||||||||
Basic |
131,277 |
|
130,776 |
|
|
131,082 |
|
131,722 |
|
||||||
Diluted |
131,732 |
|
131,432 |
|
|
131,799 |
|
132,734 |
|
||||||
|
|
|
|
|
|
||||||||||
Dividends declared per share |
$ |
0.26 |
|
$ |
0.25 |
|
|
$ |
1.04 |
|
$ |
1.00 |
|
National Instruments |
|||||||
Condensed Consolidated Statements of Cash Flows |
|||||||
(in thousands) |
|||||||
|
Years Ended December 31, |
||||||
|
2020 |
|
2019 |
||||
|
(unaudited) |
|
|
||||
Cash flow from operating activities: |
|
|
|||||
Net income |
$ |
143,659 |
|
$ |
162,151 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|||||
Depreciation and amortization |
87,064 |
|
73,541 |
|
|||
Stock-based compensation |
58,376 |
|
51,438 |
|
|||
Disposal gain on sale of business/asset |
(159,753) |
|
(26,842) |
|
|||
Deferred income taxes |
7,089 |
|
(12,680) |
|
|||
Net change in operating assets and liabilities |
44,332 |
|
(23,203) |
|
|||
Net cash provided by operating activities |
180,767 |
|
224,405 |
|
|||
|
|
|
|||||
Cash flow from investing activities: |
|
|
|||||
Capital expenditures |
(49,652) |
|
(60,857) |
|
|||
Proceeds from sale of assets/business, net of cash divested |
160,266 |
|
32,492 |
|
|||
Capitalization of internally developed software |
(4,054) |
|
(9,065) |
|
|||
Additions to other intangibles |
(1,441) |
|
(1,209) |
|
|||
Acquisitions of equity-method investments |
(9,761) |
|
(13,670) |
|
|||
Acquisitions, net of cash received |
(334,981) |
|
— |
|
|||
Purchases of short-term investments |
(206,330) |
|
(185,267) |
|
|||
Sales and maturities of short-term investments |
384,652 |
|
219,628 |
|
|||
Net cash used by investing activities |
(61,301) |
|
(17,948) |
|
|||
|
|
|
|||||
Cash flow from financing activities: |
|
|
|||||
Proceeds from term loan |
170,000 |
|
— |
|
|||
Payments of term loan |
(71,250) |
|
— |
|
|||
Proceeds from revolving line of credit |
20,000 |
|
— |
|
|||
Payments of revolving line of credit |
(20,000) |
|
— |
|
|||
Debt issuance costs |
(1,893) |
|
— |
|
|||
Proceeds from issuance of common stock |
31,947 |
|
33,191 |
|
|||
Repurchase of common stock |
(48,713) |
|
(171,316) |
|
|||
Dividends paid |
(136,545) |
|
(131,855) |
|
|||
Other |
— |
|
(837) |
|
|||
Net cash used by financing activities |
(56,454) |
|
(270,817) |
|
|||
|
|
|
|||||
Impact of changes in exchange rates on cash |
2,604 |
|
(410) |
|
|||
|
|
|
|||||
Net change in cash and cash equivalents |
65,616 |
|
(64,770) |
|
|||
Cash and cash equivalents at beginning of period |
194,616 |
|
259,386 |
|
|||
Cash and cash equivalents at end of period |
$ |
260,232 |
|
$ |
194,616 |
|